Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05874635 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)

StatusActive, Not Recruiting
PhaseNot applicable
SponsorSignos Inc
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v4
  2. Re-verified, no change to tracked fieldsv3
  3. Primary endpoints revised (3)
    • Study title expanded, about 1 word
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Signos Inc
3 trials monitored
See all monitored trials
Diabetes
5,087 trials monitored
See 222 trials at risk
Obesity
3,874 trials monitored
See 152 trials at risk
Type 2 Diabetes
2,231 trials monitored
See 111 trials at risk
The use of continuous glucose monitoring (CGM) in earlier data has inspired behavioral changes leading to improved adherence to an exercise plan in individuals and eating habits in people with diabetes. Mobile health (mHealth) platforms provide satisfactory, easy-to-use tools to help participants in the pursuit of weight change goals. We hypothesize that the use of CGM data and the Signos mHealth platform will assist with weight control in a population of people with type 2 diabetes mellitus who are not using insulin.
Trial Details
NCT Number NCT05874635
Lead Sponsor Signos Inc
Conditions
(from sponsor)		 Weight Loss, Metabolic Syndrome, Diabetes Mellitus, Type 2, Central Obesity, Insulin Resistance, Glucose Intolerance, Metabolic Glucose Disorders
Related terms Diabetes Mellitus, Type 2, Glucose Intolerance, Glucose Metabolism Disorders, Insulin Resistance, Metabolic Syndrome, Obesity, Abdominal, Weight Loss
Enrollment 20,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov